(Reuters) - The U.S. Food and Drug Administration approved Aclaris Therapeutics Inc’s topical drug to treat a common kind of skin growth called seborrheic keratoses, the company said on Friday.
The drug, Eskata, would be the first FDA-approved non-invasive treatment for the condition, Aclaris said.
Seborrheic keratoses are non-cancerous skin growths that affect more than 83 million American adults, according to Aclaris.
Current therapies for treating such skin lesions include cryosurgery, burning, cutting or scraping — all generally painful options that may also cause pigmentation and infection.
Eskata is expected to be commercially available in the spring of 2018.
Shares of Malvern, Pennsylvania-based Aclaris rose 9.2 percent to $24.72 in premarket trading.
Reporting by Divya Grover in Bengaluru; editing by Sai Sachin Ravikumar
